Diagnostic biomarkers for fibrotic lung disease have not been validated; however, increased circulating fibrocytes have been suggested in patients with IPF, though data regarding vascular endothelial growth factor is contradictory. Chitotriosidase detected in bronchoalveolar lavage fluid may possibly correlate with the severity of sarcoidosis.
Functional parameters used to monitor and evaluate disease progression include the percentage value on the predicted forced vital capacity, the diffusion capacity of the lung for carbon monoxide, and 6-minute-walk-distance data. Worsening dyspnea is also a primary indicator of disease progression, as are acute exacerbations.
Learn more about the treatment of PF-ILD.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Zab Mosenifar. Fast Five Quiz: Interstitial Lung Disease Progressive Fibrosing Management - Medscape - Feb 01, 2022.